Evaluation of the Knees of Asymptomatic Kangoo Jumpers with MR Imaging.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Conflicts of Interest The authors declare that they have no conflicts of interest. 16. Orthop J Sports Med. 2023 Sep 11;11(9):23259671231184400. doi: 10.1177/23259671231184400. eCollection 2023 Sep. Safety and Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Patellar Tendinopathy (With Gap >3 mm) in Patients: 12-Month Follow-up Results of a Phase 1/2 Clinical Trial. Soler R(1), Rodas G(2)(3), Rius-Tarruella J(1), Alomar X(4), Balius R(5), Ruíz-Cotorro Á(6)(7), Masci L(8), Maffulli N(9)(10)(11), Orozco L(1). Author information: (1)Institut de Teràpia Regenerativa Tissular (ITRT), Centro Médico Teknon Hospital, Barcelona, Spain. (2)Medical Department FC Barcelona, Barcelona, Spain. (3)Sports Medicine Unit, Clínic Hospital and Sant Joan de Déu Hospital, Barcelona, Spain. (4)Diagnóstico por la Imagen, Clínica Creu Blanca, Barcelona, Spain. (5)Consell Català de l'Esport, Generalitat de Catalunya, Barcelona, Spain. (6)Servicios Médicos de la Real Federación Española de Tenis (RFET), Barcelona, Spain. (7)Director de la Clínica Tenis Teknon, Centro Médico Teknon, Barcelona, Spain. (8)Institute of Sports Exercise and Health (ISEH), London, UK. (9)Department of Musculoskeletal Disorders, University of Salerno School of Medicine, Surgery and Dentistry, Salerno, Italy. (10)Center of Sports and Exercise Medicine, Queen Mary University of London, London, UK. (11)School of Pharmacy and Bioengineering, Keele University School of Medicine, Staffordshire, UK. BACKGROUND: In a previous study, the authors found that at 6 months after treatment with a 20 × 106 dose of bone marrow-derived mesenchymal stem cells (BM-MSCs), patients showed improved tendon structure and regeneration of the gap area when compared with treatment using leukocyte-poor platelet-rich plasma (Lp-PRP). The Lp-PRP group (n = 10), which had not seen tendon regeneration at the 6-month follow-up, was subsequently offered treatment with BM-MSCs to see if structural changes would occur. In addition, the 12-month follow-up outcomes of the original BM-MSC group (n = 10) were evaluated. PURPOSE: To evaluate the outcomes of all patients (n = 20) at 12 months after BM-MSC treatment and observe if the Lp-PRP pretreated group experienced any type of advantage. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: Both the BM-MSC and original Lp-PRP groups were assessed at 12 months after BM-MSC treatment with clinical examination, the visual analog scale (VAS) for pain during daily activities and sports activities, the Victorian Institute of Sport Assessment-Patella score for patellar tendinopathy, dynamometry, and magnetic resonance imaging (MRI). Differences between the 2 groups were compared with the Student t test. RESULTS: The 10 patients originally treated with BM-MSCs continued to show improvement in tendon structure in their MRI scans (P < .0001), as well as in the clinical assessment of their pain by means of scales (P < .05). Ten patients who were originally treated with Lp-PRP and then with BM-MSCs exhibited an improvement in tendon structure in their MRI scans, as well as a clinical pain improvement, but this was not significant on the VAS for sports (P = .139). Thus, applying Lp-PRP before BM-MScs did not yield any type of advantage. CONCLUSION: The 12-month follow-up outcomes after both groups of patients (n = 20) received BM-MSC treatment indicated that biological treatment was safe, there were no adverse effects, and the participants showed a highly statistically significant clinical improvement (P < .0002), as well as an improvement in tendon structure on MRI (P < .0001). Preinjection of Lp-PRP yielded no advantages. © The Author(s) 2023. DOI: 10.1177/23259671231184400 PMCID: PMC10498712